Twitter  |    LinkedIn

Training the Next Generation of Innovators in Dermatology

Now Viewing Articles

Advancing Innovation in Dermatology is pleased to make available our collection of scholar articles, industry news, and interviews with the professionals accelerating innovation in skin health and patient care. This content is yet another way beyond our in-person and virtual events to strengthen the community of innovators we aim to build and maintain.

Oct 20, 2016
By: Advancing Innovation in Dermatology

Shuai Xu, James Allred, Brandon Kirsch, Adam Raff, R. Rox Anderson, William Ju

Since the 1950s, the number of new drugs approved by the Food and Drug Administration per $1 billion invested in research and development has fallen 80-fold (Scannell et al., 2012).

Dermatology is not immune to this trend. Topical drug innovation has fallen by 45% from 2000 to 2004 compared with 2010 to 2014 with the majority of approvals constituting dosage form changes (Walter and Xu, 2015). Certainly, there have been impressive drug developments for melanoma and psoriasis over the last decade.

Source: Full Article | JID, November 2016, Volume 136, Issue 11, Pages 2113–2115 .

Download PDF